PFE250110P31000
- 0.00
- 0.000.00%
Pfizer Newsroom
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Zentalis Pharma Says FDA Grants Fast Track Status on Azenosertib Cancer Drug Candidate
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Pfizer Inc. (NYSE:PFE) Is Largely Controlled by Institutional Shareholders Who Own 68% of the Company
Daily short sale tracking: IonQ Inc's short volume increased by 9 million, with a short sale ratio of 9%
IonQ Inc(IONQ.US) ranked top of the list had the largest change in short volume (9.2 million shares), and the short volume ratio of TELUS(TU.US) reached 46.15%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
Today's Analyst Rating | Blackrock Price Target Raised to $1215 by Deutsche Bank, UBS Cuts Its Price Target Cut on Pfizer to $29
Jan 9, Wall Street analysts have updated their stock ratings today including $Blackrock(BLK.US)$ and $Pfizer(PFE.US)$.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
San Francisco Police Cancel Time Off as Healthcare Execs Descend -- Barrons.com
Express News | FDA: Hospira's Methotrexate Sodium Injection Injection, 25 Mg/1 Ml Discontinued- Website
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Oak Tree Capital's Marks: New things are prone to bubbles, currently private equity buying S&P 500, with a 10-year yield of only ±2%.
Max recently released a memorandum titled "Revisiting the Bubble," stating that investors are currently betting on the leading high-tech companies to maintain their dominance. However, he believes that it is not easy to stay ahead, as new technologies and competitors can surpass existing market leaders at any time. When people assume that "things can only get better" and Buy based on that, the impact of negative news can be particularly severe. He specifically pointed out the frenzy over AI and how this positive sentiment may spread to other Technology sectors.
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer -- Barrons.com
Pfizer Is Maintained at Neutral by UBS
Pfizer Analyst Ratings
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder
UBS Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $29
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $32
The FDA states that GlaxoSmithKline (GSK.US) and Pfizer (PFE.US) RSV vaccines must include warnings about the rare risk of paralysis.
The FDA stated that a vaccine produced by GlaxoSmithKline (GSK.US) and Pfizer (PFE.US) must include a warning about the potential increased risk of a rare neurological side effect.